Slide 1: A world free of postoperative complications. Q4 and 2023 summary
A world free of postoperative complications. Precision-based patient monitoring. Senzime delivers advanced monitoring solutions that are at the forefront of precision-based care. Our portfolio, powered by proprietary smart algorithms, equips anesthesia providers with real-time data and insights, fac
Slide 2: This is Senzime
This is Senzime. Senzime is a global medical technology company driving a 1 digital and clinical shift within patient monitoring - addressing over 100 million patients and a market valued >40 billion SEK. Our solutions enable precision-based patient monitoring to 2 help optimize drug doses and elimi
Slide 3: Senzime 2023: Commercial Breakthrough
Senzime 2023: Commercial Breakthrough Total revenues 2023 (MSEK) 1 Net sales in 2023 reached SEK 35.8 m (14.0). Overall 40 growth 155%, monitors +143% and disposables +166% +155% 35 2 Growth mainly driven by major hospital wins in the 30 US market and recurring sales of disposable sensors 25 25 3 Pr
Slide 4: Senzime Q4 2023: Accelerated Growth Rate
Senzime Q4 2023: Accelerated Growth Rate Q4 revenues (MSEK) 1 Net sales for Q4 reached SEK 10.9 m (4.6). Overall 12 growth 138%, monitors 162% and disposables 126% +138% 10 2 Strong growth in US market with net sales increasing more than four-fold to SEK 8.3 m (1.8 m) by new hospital wins and recurr
Slide 5: Installed base of monitors grows, drives sales of disposable sensors
Installed base of monitors grows, drives sales of disposable sensors Shipped base of TetraGraph systems1 Shipped TetraSens disposable sensors 2023 (units) 2 500 120 000 +148% 100 000 2 000 Installed base drives use of consumables 80 000 1 500 60 000 1 000 40 000 500 20 000 0 0 Q1 2021 Q2 Q3 Q4 Q1 Q2
Slide 6: Strong sales of disposable sensors drives rapid growth rate and margins
Strong sales of disposable sensors drives rapid growth rate and margins Net sales rolling-12 months (kSEK) Sales of TetraSens, rolling-12 months (kSEK) 40 000 20 000 36 000 18 000 32 000 16 000 28 000 14 000 24 000 12 000 20 000 10 000 16 000 8 000 12 000 6 000 8 000 4 000 4 000 2 000 0 0 Q1 Q2 Q2 Q
Slide 7: TetraGraph customer (hospital) growth 2023
TetraGraph customer (hospital) growth 2023 Number of active hospital accounts, end of period* 200 180 160 140 120 100 80 60 40 20 0 End of 2022 Jan-March April-May Jan-July Aug-Sept Oct-Dec * Excludes accounts in Japan, South Korea and smaller distribution markets.
Slide 8: Utilization rate driven by leading hospital accounts
Utilization rate driven by leading hospital accounts Utilization rate, TetraSens use per week1 6,0 4,8 5,0 3,8 3,9 4,0 3,6 3,4 3,2 3,0 2,6 2,5 2,0 2,0 1,9 2,0 1,6 1,7 1,6 1,2 0,8 1,0 0,0 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 All deployed accounts Key deployed accounts
Slide 9: Spotlight: US market
Spotlight: US market Utilization rate US-market 6,0 5,7 5,0 4,6 4,4 4,2 4,1 4,0 3,6 3,5 3,0 2,8 2,7 2,8 2,5 2,5 2,2 2,0 1,6 1,0 0,7 0,4 0,0 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Key d eployed accounts All deployed accounts
Slide 10: Spotlight US market: Selected 2023 key wins
Spotlight US market: Selected 2023 key wins 1 Leading US Integrated Delivery Network (IDN) contract serving several million members mainly on the US West Coast. Estimating full installation to reach close to 6 Major New York metropolitan 300 TetraGraph systems when fully deployed with potential of a
Slide 11: The financials of a large US customer win - example
The financials of a large US customer win - example Accumulated orders of sensors, US hospital § Larger clinical account with 65 TetraGraphs 35 000 in use. 30 000 § Clinical protocol in place to run TetraGraph on all patients with paralytic agents. 25 000 § Took 3-4 months to reach a high utilizatio
Slide 12: Why leading hospitals choose the TetraGraph system
Why leading hospitals choose the Helping the anesthesiologist secure the right dose of paralytics TetraGraph system and indicate when its safe for the patient to breathe again. 1 LEADING SOLUTION BACKED BY SCIENCE The TetraGraph is powered by a 5th generation proprietary EMG-algorithm for maximum ac
Slide 13: Widespread clinical guidelines in support of the TetraGraph system
Widespread clinical guidelines in support of the TetraGraph system 2022/23 European Society Anesthetists (ESA) guidelines 2021 EI Grupo Espanol 2020 de Rehabilitacion Canadian Multimodal 2019 Anesthesiology Society, Rev 1 Italian Society of Anesthesia, Analgesia, 2018 Reanimation and 2024 Consensus
Slide 14: Research recap: Getting to clinical guidelines
Research recap: Getting to clinical guidelines Search term: Search term: “Neuromuscular Block” “Neuromuscular Monitoring” 11,002 studies 4,886 studies published since 1948 published since 1960
Slide 15: Strengthened clinical validation data supporting the TetraGraph system
Strengthened clinical validation data supporting the leading performance of the TetraGraph system 1 2 Validating Clinically Important Neuromuscular Validation of a convolutional neural network that Monitoring Endpoints: Mechanomyography reliably identifies EMG compound motor action (MMG) vs. Electro
Slide 16: Introducing the most sensitive EMG-electrode
Introducing the most sensitive EMG-electrode
Slide 17: a*RaN
o A a*RaN <a Mab eeEVA—IL MIRED UV IORLGAEDADEUENT USAT, AIS APB MLIC KD MERE HN-100 EXIUYILTUNET Eamnlgms's-2024p=7xP0112000 ARB BVORMMECRANTMBESAT. oa . ZOBOMELEAMNTSCET. HBEOREE ( A es _i PET SRETS. — Ss @SENZIME
Slide 18: Product market mix and move to in-house production drives gross margin
Product market mix and move to in-house production drives gross margin Development of COGS (MSEK) and Gross Margin rolling-12 months (%) 30 80% 68,6% 68,7% 69,8% 70% 25 64,6% 62,0% 60% 57,4% 56,2% 20 53,7% 54,3% 53,2% 50% 48,2% 15 40,9% 40,2% 40% 30% 10 20% 5 10% 0 0% Q4 2020 Q1 2021 Q2 2021 Q3 2021
Slide 19: Sales growth with operating expense control
Sales growth with operating expense control Operating expenses (kSEK). Direct and including currency adjustments 50 000 45 000 40 000 35 000 30 000 25 000 20 000 15 000 10 000 5 000 0 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Direct OPEX OPEX incl currency effects
Slide 20: SEK 265 million raised in 2023 from long-term investors
SEK 265 million raised in 2023 from long-term investors securing Senzime’s growth plans As of Dec 14, 2023 Number of Capital 92 MSEK in a rights issue raised at Ten largest shareholders 1 shares (%) at SEK 7.25 in Feb 2023 from mainly Crafoord family and the Crafoord Foundation 19,703,456 16,5 exist
Slide 21: US OTCQX market cross listing
US OTCQX market cross listing • Senzime has over 10% its shares held by US based investors. • To attract more US based investors and enable trading of the Senzime-share, it is traded on OTCQX markets since October 2023 via the ticker SNZZF. • OTCQX is a cost-effective and smart alternative to listin
Slide 22: 2024 US Commercial expansion
2024 US Commercial expansion • Expansion of its US-based sales team with additional Area Territory Managers. • Recruitment of Michael Noble as Vice President Global Marketing and joins the Executive Leadership Team. • Relocation of US headquarters from Boston to St. Louis, to enable more rapid, cost
Slide 23: The Senzime 300 equation
The Senzime 300 equation 300 x 30 x 4 = 300 Hospital Average # of Average use of Million SEK in accounts TetraGraphs per TetraSens per consumable sales hospital monitor and week Goal is that Senzime shall reach sales of around 300 MSEK in 2025, reach a market share of at least 10% in its addressed m
Slide 24: Wrap-up messages
Wrap-up messages 1 2023 was a landmark commercial breakthrough year for Senzime. 2 Senzime has a leading position in a once-in-a-decade market window to capitalize on new clinical guidelines. 3 Positive outlook targeting a 100 million patient market backed by long-term investors and run by a brillia
Slide 25: Thank you.
Thank you. Our mission is to safeguard every patient's journey, ensuring a complication-free experience from anesthesia to recovery. We do this by delivering advanced monitoring solutions that are at the forefront of precision-based care. Our portfolio, powered by proprietary smart algorithms, equip